BioStem Technologies, Inc., a MedTech company specializing in perinatal tissue-derived products for advanced wound care, announced that company management will present at the 46th Annual TD Cowen Healthcare Conference in Boston, Massachusetts. The presentation is scheduled for Monday, March 2, 2026, at 3:50 pm ET. This event provides BioStem with a significant platform to engage with investors and industry stakeholders during a key healthcare investment conference.
The company focuses on developing, manufacturing, and commercializing allografts for regenerative therapies using its proprietary BioRetain® processing method. This method is designed to maintain growth factors and preserve tissue structure, which is crucial for effective wound healing and tissue regeneration. BioStem's quality management system has been accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and current Good Manufacturing Processes, ensuring high standards in its product offerings.
BioStem's portfolio includes brands such as VENDAJE®, VENDAJE AC®, American Amnion™, American Amnion AC™, and the Neox® and Clarix® product lines. These products are used in advanced wound care applications, addressing complex medical needs. The presentation at the TD Cowen conference is important as it allows BioStem to showcase its innovations and business strategy to a focused audience of healthcare investors and analysts, potentially influencing investment decisions and industry recognition.
Interested parties can access live and archived webcasts of the presentation through the investors section of the company's website at https://ir.biostemtechnologies.com. This accessibility ensures broader reach and transparency for stakeholders who cannot attend in person. The conference participation underscores BioStem's commitment to advancing regenerative medicine and highlights the growing importance of perinatal tissue-based therapies in the healthcare sector. For more information on the company, visit https://biostemtechnologies.com. Additional news and updates related to BioStem are available in the company's newsroom at https://tinyurl.com/bsemnewsroom.
